Standout Papers

Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metasta... 2014 2026 2018 2022 328
  1. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study (2014)
    Timothy Price, Marc Peeters et al. The Lancet Oncology

Immediate Impact

1 from Science/Nature 74 standout
Sub-graph 1 of 19

Citing Papers

Exploring treatment options in cancer: tumor treatment strategies
2024 Standout
Colorectal cancer
2024 Standout
4 intermediate papers

Works of Roger Sidhu being referenced

Comprehensive analysis of KRAS and NRAS mutations as predictive biomarkers for single agent panitumumab (pmab) response in a randomized, phase III metastatic colorectal cancer (mCRC) study (20020408).
2013
Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC).
2013
and 3 more

Author Peers

Author Last Decade Papers Cites
Roger Sidhu 703 378 162 246 29 885
Federico Nasroulah 809 389 149 152 28 969
L. Leong 645 234 143 141 39 1.0k
Vicente Alonso-Orduña 809 392 131 136 23 981
M. Machiavelli 748 253 227 187 32 992
Jian-Ming Xu 569 335 113 150 15 803
Claus-Christoph Steffens 946 467 147 161 18 1.1k
C. Schlichting 804 396 126 139 16 1.1k
J. Kalmus 692 288 111 354 22 995
G Paoletti 757 342 92 135 28 944
Christian Lerchenmüller 565 411 163 187 48 857

All Works

Loading papers...

Rankless by CCL
2026